A Phase 1, Open-label, Non-Randomized Study to Evaluate the Safety and Tolerability of [Tc-99m]-RPI T-087 Injection as an Imaging Marker for COX-2 in Subjects With Osteoarthritis of the Knee Compared to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2019
Price : $35 *
At a glance
- Drugs Technetium-99m RPI T 087 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Reiley Pharmaceuticals
- 11 Jan 2019 Planned End Date changed from 31 Jan 2019 to 30 Jun 2019.
- 11 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 May 2019.
- 16 Aug 2018 Status changed from not yet recruiting to recruiting.